This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

CRESEMBA® in Invasive Aspergillosis: Efficacy

In the SECURE trial, CRESEMBA demonstrated comparable efficacy to voriconazole in invasive aspergillosis*1. This allows you to prescribe CRESEMBA with confidence in your aspergillosis patients.

*The non-inferiority margin was 10% for adjusted treatment differences between CRESEMBA and voriconazole; an upper 95% CI less than 10% suggests that CRESEMBA is non-inferior to voriconazole.

Explore more


Access dosing information

  1. ​​​​​​​​​​​​​​​​​​​​​Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voricanazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE); a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
PP-CRB-GBR-1203. August 2021

Invasive Aspergillosis (Quick Links)

Safety Profile

 CRESEMBA safety information

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020